Kura Oncology (NASDAQ:KURA) COO Kathleen Ford Sells 6,892 Shares

Kura Oncology, Inc. (NASDAQ:KURA) COO Kathleen Ford sold 6,892 shares of the firm’s stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $8.94, for a total transaction of $61,614.48. Following the transaction, the chief operating officer owned 63,375 shares of the company’s stock, valued at approximately $566,572.50. This represents a 9.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Kura Oncology Stock Down 0.9%

Shares of KURA opened at $8.97 on Tuesday. The stock has a market cap of $778.60 million, a price-to-earnings ratio of -3.97 and a beta of 0.19. The company has a quick ratio of 6.16, a current ratio of 6.16 and a debt-to-equity ratio of 0.02. Kura Oncology, Inc. has a 12 month low of $5.41 and a 12 month high of $19.93. The company has a 50-day moving average price of $7.39 and a two-hundred day moving average price of $6.65.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.90). The business had revenue of $15.29 million for the quarter, compared to analysts’ expectations of $64.95 million. Equities analysts predict that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.

Wall Street Analyst Weigh In

KURA has been the subject of a number of research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research note on Thursday, June 26th. Guggenheim initiated coverage on shares of Kura Oncology in a research note on Thursday, September 4th. They issued a “neutral” rating for the company. Wall Street Zen upgraded shares of Kura Oncology from a “sell” rating to a “hold” rating in a research note on Sunday, August 17th. JMP Securities cut their target price on shares of Kura Oncology from $28.00 to $24.00 and set a “market outperform” rating for the company in a research note on Monday, August 11th. Finally, Wedbush reiterated an “outperform” rating and issued a $36.00 target price on shares of Kura Oncology in a research note on Friday, June 20th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Kura Oncology currently has a consensus rating of “Moderate Buy” and an average target price of $24.10.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. BVF Inc. IL raised its position in shares of Kura Oncology by 202.0% during the 1st quarter. BVF Inc. IL now owns 7,754,129 shares of the company’s stock valued at $51,177,000 after acquiring an additional 5,186,660 shares during the last quarter. EcoR1 Capital LLC raised its position in shares of Kura Oncology by 59.1% during the 2nd quarter. EcoR1 Capital LLC now owns 4,200,000 shares of the company’s stock valued at $24,234,000 after acquiring an additional 1,559,702 shares during the last quarter. Armistice Capital LLC raised its position in shares of Kura Oncology by 13.3% during the 1st quarter. Armistice Capital LLC now owns 6,572,000 shares of the company’s stock valued at $43,375,000 after acquiring an additional 772,000 shares during the last quarter. Qube Research & Technologies Ltd raised its position in shares of Kura Oncology by 63.0% during the 2nd quarter. Qube Research & Technologies Ltd now owns 1,911,886 shares of the company’s stock valued at $11,032,000 after acquiring an additional 738,761 shares during the last quarter. Finally, AQR Capital Management LLC raised its position in shares of Kura Oncology by 407.8% during the 1st quarter. AQR Capital Management LLC now owns 760,332 shares of the company’s stock valued at $5,018,000 after acquiring an additional 610,604 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.